TaiMed Biologics Inc. (TPEX:4147)
Taiwan · Delayed Price · Currency is TWD 53.70
+0.50 (0.94%)
At close: Feb 11, 2026
TaiMed Biologics Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -219.71 | -201.83 | -194.81 | -269.29 | -470.93 | -183.3 |
Depreciation & Amortization | 150.35 | 150.1 | 150.67 | 151.73 | 152.13 | 137.12 |
Other Amortization | 3.12 | 4.18 | 4.72 | 4.72 | 4.53 | 2.66 |
Loss (Gain) From Sale of Assets | 1.61 | 2.32 | - | - | 24.18 | 7.84 |
Loss (Gain) From Sale of Investments | 1.18 | - | 29.05 | 122.81 | -26.76 | 63.13 |
Stock-Based Compensation | 8.14 | 25.36 | 10.51 | 12.27 | 10.22 | 16.68 |
Other Operating Activities | 109.82 | 80.78 | 5.82 | 168.85 | 101.38 | -15.5 |
Change in Accounts Receivable | 42.54 | 57.47 | -62.24 | 59.54 | 97.94 | -53.59 |
Change in Inventory | 182.8 | 185.47 | 110.85 | -382.84 | 14.84 | -384.99 |
Change in Accounts Payable | 1.83 | -12.74 | 13.41 | -122.49 | 116.79 | -130.24 |
Change in Unearned Revenue | -83.92 | -113.31 | -27.93 | -339.16 | 113.91 | 83.16 |
Change in Other Net Operating Assets | -539.95 | -557.36 | -65.64 | -11.33 | -349.5 | 255.09 |
Operating Cash Flow | -342.2 | -379.55 | -25.6 | -605.21 | -211.28 | -201.94 |
Capital Expenditures | -6.93 | -8.06 | -6.15 | -3.56 | -9.69 | -53.61 |
Sale of Property, Plant & Equipment | - | - | - | - | 0.41 | 2 |
Sale (Purchase) of Intangibles | -0.1 | -11.3 | - | -1.21 | -3.87 | -332.16 |
Investment in Securities | 192.9 | -695.39 | -12.88 | 110.88 | 204.07 | 273.36 |
Other Investing Activities | 0.09 | -0.1 | 2.58 | - | - | 1.25 |
Investing Cash Flow | 185.96 | -714.84 | -16.46 | 106.12 | 190.92 | -109.16 |
Short-Term Debt Issued | - | - | - | 200 | - | - |
Long-Term Debt Issued | - | - | - | - | - | 536 |
Total Debt Issued | - | - | - | 200 | - | 536 |
Short-Term Debt Repaid | - | -200 | - | - | - | - |
Long-Term Debt Repaid | - | -28.98 | -16.05 | -1.98 | -1.93 | -1.91 |
Total Debt Repaid | -29.35 | -228.98 | -16.05 | -1.98 | -1.93 | -1.91 |
Net Debt Issued (Repaid) | -29.35 | -228.98 | -16.05 | 198.02 | -1.93 | 534.09 |
Issuance of Common Stock | 8.89 | 1,645 | 35.28 | 10.31 | 4.71 | 1.95 |
Other Financing Activities | -0.92 | -4.27 | - | 0.05 | 0.01 | - |
Financing Cash Flow | -21.38 | 1,412 | 19.23 | 208.38 | 2.79 | 536.04 |
Foreign Exchange Rate Adjustments | -3.8 | 11.54 | -0.28 | 13.21 | -2.9 | -5.78 |
Net Cash Flow | -181.42 | 329.22 | -23.1 | -277.51 | -20.47 | 219.16 |
Free Cash Flow | -349.13 | -387.61 | -31.75 | -608.77 | -220.96 | -255.55 |
Free Cash Flow Margin | -57.50% | -63.52% | -6.46% | -108.13% | -53.44% | -35.37% |
Free Cash Flow Per Share | -1.28 | -1.45 | -0.13 | -2.41 | -0.88 | -1.01 |
Cash Interest Paid | 11.25 | 12.71 | 14.76 | 9.88 | 7.44 | 3.84 |
Levered Free Cash Flow | -174.24 | -268.47 | 82.39 | -217.42 | -191.55 | -673.15 |
Unlevered Free Cash Flow | -167.23 | -260.59 | 91.65 | -211.11 | -186.9 | -670.59 |
Change in Working Capital | -396.71 | -440.47 | -31.56 | -796.29 | -6.02 | -230.56 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.